Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Prostemics Co., Ltd.
  6. News
  7. Summary
    A203690   KR7203690003

PROSTEMICS CO., LTD.

(A203690)
SummaryChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Prostemics Co., Ltd. announced that it expects to receive KRW 24 billion in funding from a group of investors

07/31/2020 EDT

Prostemics Co., Ltd. (KOSDAQ:A203690) announced a private placement to issue Series 2 non-guaranteed private convertible bonds for KRW 20,000,000,000 and series 3 non-secured non-separable private equity bonds for KRW 4,000,000,000 for aggregate gross proceeds of KRW 24,000,000,000 on July 31, 2020. The transaction will include participation for series 3 bonds from new investors Industrial Bank of Korea, Investment Arm for KRW 2,500,000,000, NH Investment & Securities Co., Ltd., Investment Arm for KRW 400,000,000, Mirae Asset Daewoo Co., Ltd., Investment Arm for KRW 100,000,000, Shinhan Investment Corp., Investment Arm for KRW 1,000,000,000 and series 2 bonds from new investors Hanyang Securities Co., Ltd., Investment arm for KRW 7,500,000,000, Samsung Securities Co. Ltd., Investment Arm for KRW 4,000,000,000, Korea Investment & Securities Co., Ltd., Investment Arm for KRW 1,000,000,000, Shinhan Investment Corp., Investment Arm for KRW 2,000,000,000, eBest Investment Securities Co., Ltd., Investment Arm for KRW 1,500,000,000, Meritz Securities Co., Ltd., Investment Arm for KRW 1,000,000,000, Susung Asset Management Co., Ltd. for KRW 1,500,000,000, NH Investment & Securities Co., Ltd., Investment Arm for KRW 1,000,000,000, and Ace Suseong New Technology Investment Fund No. 10 for KRW 500,000,000. The series 2 and series 3 bonds will mature on August 04, 2025 and February 4, 2023 respectively. The bonds are of zero-coupon. The bonds are 100% convertible common shares of the company at the conversion price of KRW 3,910 per share. The conversion period for series 2 will starts from August 4, 2021 and ends on January 4, 2023 and for series 3 bonds it starts from August 4, 2021 and ends on July 4, 2025. The subscription and payment date is August 4, 2020. The transaction has been approved by the board of directors of the company.


© S&P Capital IQ 2020
Stocks mentioned in the article
ChangeLast1st jan.
BIKE24 HOLDING AG -1.95% 23.12 Delayed Quote.0.00%
PROSTEMICS CO., LTD. 1.31% 3085 End-of-day quote.-29.89%
All news about PROSTEMICS CO., LTD.
08/12California weed supplier HERBL in talks to go public via SPAC merger - source..
RE
08/12California weed supplier HERBL in talks to go public via SPAC merger - source..
RE
06/21Investors brace for annual Russell index rebalancing with pandemic imprint
RE
06/18Investors brace for annual Russell index rebalancing with pandemic imprint
RE
2020Prostemics Co., Ltd. announced that it has received KRW 24 billion in funding..
CI
2020Prostemics Co., Ltd. announced that it expects to receive KRW 24 billion in f..
CI
2018Tranche Update on Prostemics Co., Ltd.'s Equity Buyback Plan announced on Aug..
CI
2018Prostemics Co., Ltd.'s Equity Buyback announced on August 10, 2017, has expir..
CI
2017Tranche Update on Prostemics Co., Ltd.'s Equity Buyback Plan announced on Aug..
CI
2017Prostemics Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth ..
CI
More news
Financials
Sales 2020 20 727 M 17,5 M 17,5 M
Net income 2020 -7 265 M -6,15 M -6,15 M
Net Debt 2020 18 176 M 15,4 M 15,4 M
P/E ratio 2020 -27,2x
Yield 2020 -
Capitalization 139 B 118 M 117 M
EV / Sales 2019 20,4x
EV / Sales 2020 10,4x
Nbr of Employees 83
Free-Float 65,5%
Chart PROSTEMICS CO., LTD.
Duration : Period :
Prostemics Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Eun-Wook Choi Co-Chief Executive Officer & Director
Byung-Soon Park Co-Chief Executive Officer & Director
Dong-Young Son Independent Director
Young-Tae Kang Independent Director
Won-Jong Lee Director
Sector and Competitors
1st jan.Capi. (M$)
PROSTEMICS CO., LTD.-29.89%118
L'ORÉAL23.10%250 458
KAO CORPORATION-14.53%29 376
SHISEIDO COMPANY, LIMITED10.87%28 763
NATURA &CO HOLDING S.A.-8.38%12 494
AMOREPACIFIC CORPORATION-7.77%9 993